{"id":60563,"date":"2026-03-23T15:29:17","date_gmt":"2026-03-23T07:29:17","guid":{"rendered":"https:\/\/flcube.com\/?p=60563"},"modified":"2026-03-23T15:29:18","modified_gmt":"2026-03-23T07:29:18","slug":"xuanzhu-biopharma-completes-anaprazole-phase-iii-enrollment-500-subject-reflux-esophagitis-trial-advances-novel-ppi","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60563","title":{"rendered":"Xuanzhu Biopharma Completes Anaprazole Phase III Enrollment \u2013 500\u2011Subject Reflux Esophagitis Trial Advances Novel PPI"},"content":{"rendered":"\n

Xuanzhu Biopharmaceutical Co., Ltd.<\/strong> (HKG: 2575<\/a>) announced completion of full enrollment<\/strong> for its Phase III clinical trial<\/strong> evaluating Anaprazole Sodium Enteric\u2011coated Tablets<\/strong> in Reflux Esophagitis (RE)<\/strong> \u2013 with all 500 subjects<\/strong> now randomized, positioning the innovative proton pump inhibitor (PPI)<\/strong> for potential label expansion<\/strong> beyond its June 2023 duodenal ulcer approval<\/strong>.<\/p>\n\n\n\n

Clinical Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575)<\/td><\/tr>
Product<\/strong><\/td>Anaprazole Sodium Enteric\u2011coated Tablets<\/td><\/tr>
Trial Status<\/strong><\/td>Phase III enrollment complete<\/strong> (n=500)<\/td><\/tr>
Indication<\/strong><\/td>Reflux Esophagitis (RE) in adults<\/td><\/tr>
Prior Approval<\/strong><\/td>June 2023<\/strong> \u2013 Duodenal ulcer (NMPA)<\/td><\/tr>
Development Origin<\/strong><\/td>Self\u2011developed by Xuanzhu<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile \u2013 Innovative PPI Design<\/h2>\n\n\n\n
Feature<\/th>Anaprazole Sodium Mechanism<\/th>Clinical Advantage<\/th><\/tr><\/thead>
Metabolic Pathway<\/strong><\/td>Non\u2011enzymatic + multi\u2011enzymatic metabolism<\/strong><\/td>Reduced dependency on single CYP pathway<\/td><\/tr>
CYP2C19 Involvement<\/strong><\/td>Only 3.5%<\/strong> metabolized via CYP2C19<\/td>Genetic stability<\/strong> \u2013 efficacy unaffected by CYP2C19 polymorphisms<\/strong> (common with omeprazole, esomeprazole)<\/td><\/tr>
Excretion<\/strong><\/td>Balanced dual\u2011channel<\/strong> \u2013 intestines + kidneys<\/td>Elimination flexibility; reduced accumulation risk<\/td><\/tr>
DDI Risk<\/strong><\/td>Lower vs. previous\u2011generation PPIs<\/td>Safer for polypharmacy patients<\/strong><\/td><\/tr>
Renal Safety<\/strong><\/td>Favorable profile<\/td>Suitable for renal insufficiency patients<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Population & Market Positioning<\/h2>\n\n\n\n
Patient Segment<\/th>Unmet Need<\/th>Anaprazole Value Proposition<\/th><\/tr><\/thead>
CYP2C19 Poor Metabolizers<\/strong><\/td>~15\u201120% of Chinese population; suboptimal PPI response with traditional agents<\/td>Consistent efficacy regardless of genotype<\/td><\/tr>
Polypharmacy Patients<\/strong><\/td>Elderly, cardiovascular, diabetes patients on multiple medications<\/td>Lower drug\u2011drug interaction risk<\/td><\/tr>
Renal Impairment<\/strong><\/td>Limited safe PPI options; dose adjustments required<\/td>Balanced excretion enables use without renal dose modification<\/td><\/tr>
Chinese Population<\/strong><\/td>Genetic polymorphism prevalence; polypharmacy trends<\/td>“Better suited for Chinese population” positioning<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n